POSTMENOPAUSAL HORMONE THERAPY AND THE INCIDENCE OF BREAST CANCER
40 YEAR TRENDS IN POSTMENOPAUSAL HORMONE THERAPY AND THE INCIDENCE OF BREAST CANCER - DISPARITIES EXIST BETWEEN BLACK AND WHITE WOMEN
“Before the advent of sentinel node biopsy essentially all women with invasive cancer had to have a complete axillary lymph node dissection…. So in the course of less than 15 years, we have gone from 100% of women with invasive cancer having a complete dissection to around 10% – that is tremendous progress in lessening the morbidity of breast cancer surgical treatment.” Dr. Peter Beitsch
You Might Also Enjoy...
40 YEAR TRENDS IN POSTMENOPAUSAL HORMONE THERAPY AND THE INCIDENCE OF BREAST CANCER - DISPARITIES EXIST BETWEEN BLACK AND WHITE WOMEN
A study presented at the annual meeting of the American Society of Clinical Oncology and published online by the NEJMindicates Exemestane, which is now used to prevent recurrences of breast cancer, can also reduce the risk of it occurring.
The American Joint Commission on Cancer or AJCC has a staging system for all cancers including melanoma.
The study out of MD Anderson reporting ‘double the mastectomy rate’ for patients treated with accelerated partial breast irradiation compared to whole breast irradiation, has created a tremendous amount of angst in the lay and medical press.